First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Amgen Inc. (AMGN): the developments shaping its investment case

    Follow the evidence affecting Amgen Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Amgen Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-17
    Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways
    Channel: Validation of novel therapeutic approaches, potential for future pipeline expansion or partnerships in cardiovascular diseases, especially given their existing cardiovascular portfolio.
    Bullish· 1-3m
    2026-09-18 · 6 reports
    Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary
    Channel: Increased competitive pressure in the obesity and metabolic disease space, potentially diverting R&D focus or market share from existing or pipeline products.
    Bearish· 3-12m
    2026-09-23 · 2 reports
    Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide
    Channel: Increased competitive landscape for next-generation obesity drugs, potentially diminishing the perceived value and market opportunity for Amgen's own pipeline assets (e.g., AMG 133).
    Bearish· 3-12m

    Event impact log

    73 events mapped to AMGN since 2026-08-12. Evidence through 2026-09-28.

    DateEventChannelDirectionHorizonImpact
    2026-09-28Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D ReallocationCompetitive landscape dynamics, R&D strategy, and investor sentiment towards GLP-1 market participants.watch3-12m0.20
    2026-09-28Eli Lilly discontinues pipeline GLP-1 candidate following efficacy reviewIndirect competitive landscape effect. Reduced potential future competition in the GLP-1 space.Bullish3-12m0.10
    2026-09-28HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830Potential future competition in oncology, specifically for KRAS targets, if HMPL-A830 progresses.watch1-5y0.20
    2026-09-28Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise leadCompetitive landscape, investor perception of pipeline strength in obesity/metabolic disorders.mixed3-12m0.20
    2026-09-28Eli Lilly Discontinues Early-Stage GLP-1 Candidate Following Efficacy ReviewReduced potential future competition in the GLP-1 market; relative strengthening of other pipeline candidates.Bullish1-3m0.10
    2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of SalesCompetitive landscape, R&D pipeline comparison, investor sentimentBullish3-12m0.30
    2026-09-28Eli Lilly Discontinues Sub-Par GLP-1 Candidate to Refocus Capital on Next-Gen FormulationsCompetitive landscape, R&D focus, market sentimentmixed3-12m0.30
    2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate Following Subpar Efficacy DataReduced future competitive pressure in the GLP-1 market from a major rival's pipeline, potentially improving the competitive outlook for other pipeline assets.Bullish3-12m0.40
    2026-09-28HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR ConjugatePotential competitive pressure in the KRAS inhibitor market, particularly for novel mechanisms.watch1-5y0.20
    2026-09-27Eli Lilly Drops Experimental Obesity Candidate; Incretins Exceed 65% of Total RevenueReduced future competitive pressure in the obesity market, potentially enhancing the long-term outlook for its own obesity pipeline assets.Bullish3-12m0.30
    2026-09-27Eli Lilly Drops Pipeline Obesity Asset as GLP-1 Franchise Exceeds 65% RevenueIndirect competitive advantage. Reduced future competition in the obesity market, potentially increasing the value of their own pipeline assets.Bullish1-5y0.30
    2026-09-27Eli Lilly discontinues developmental obesity drug over unmet efficacy thresholdIndirectly, as a major pharmaceutical company with its own R&D pipeline, this event could lead to increased investor scrutiny on the efficacy and diversification of other companies' developmental assets, particularly in competitive therapeutic areas.watch3-12m0.30
    2026-09-27Eli Lilly Drops Experimental Obesity Candidate While Core GLP-1s Exceed 65% of RevenueIncreased scrutiny on the obesity drug pipeline and R&D efficiency across the industry, potentially impacting investor sentiment towards companies with early-stage or unproven metabolic assets.watch3-12m0.30
    2026-09-27Eli Lilly Discontinues Developmental GLP-1 Candidate Over Efficacy StandardsCompetitive landscape and R&D strategy in the metabolic space. The event emphasizes the difficulty of developing competitive GLP-1s, which could be seen as both a challenge and an opportunity for companies with different mechanisms of action or later-stage candidates.mixed3-12m0.30
    2026-09-26C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker DataPotential future competition in the multiple myeloma market, particularly for bispecific antibodies like teclistamab.watch3-12m0.20
    2026-09-26C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMSIndirect competitive landscape implications in multiple myeloma.watch3-12m0.20
    2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialIncreased competitive pressure in the kidney disease therapeutic area, potentially impacting future market share for existing or pipeline drugs.Bearish3-12m0.25
    2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinBroad pharmaceutical company with existing presence in nephrology; potential for increased R&D focus or competitive response.watch3-12m0.10
    2026-09-23Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli LillyWhile not directly competing with GLP-1s, the success and expansion of the GLP-1 market, especially with oral options, could shift R&D focus and investor attention away from other metabolic or obesity-related drug pipelines, potentially impacting future market opportunities.Bearish1-5y0.30
    2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial for EnicepatideIncreased competitive landscape for next-generation obesity drugs, potentially diminishing the perceived value and market opportunity for Amgen's own pipeline assets (e.g., AMG 133).Bearish3-12m0.50
    2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial of Dual GLP-1/GIP Agonist EnicepatideIncreased competitive pressure in the obesity drug market, potentially impacting the future market share and commercial viability of its own GLP-1 pipeline assets.Bearish1-5y0.50
    2026-09-23Novo Rebrands to 'Novo' and Deploys Oral GLP-1 Pill in Market Share DefenseIncreased competitive pressure in the broader metabolic disease market, potentially impacting future pipeline products or existing drugs for related conditions.Bearish3-12m0.40
    2026-09-18Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formularyIncreased competitive pressure in the obesity and metabolic disease space, potentially diverting R&D focus or market share from existing or pipeline products.Bearish3-12m0.40
    2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverageIntensified competition in the metabolic disease space, potentially diverting R&D focus and market attention from other therapeutic areas.Bearish3-12m0.60
    2026-09-18Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM CoverageIncreased competitive pressure in the obesity/metabolic disease market, potentially impacting future pipeline assets or existing therapies.Bearish1-5y0.50
    2026-09-18Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo ExpandsIncreased competition in the obesity/metabolic disease space, potentially diverting R&D resources or impacting future market share for pipeline drugs.Bearish3-12m0.50
    2026-09-18Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expandsIncreased competition in the obesity/metabolic disease space from highly effective GLP-1s, potentially diverting R&D focus or market share from Amgen's pipeline assets.Bearish1-5y0.40
    2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverageIncreased competitive pressure in the obesity/metabolic disease market, potentially impacting the future market potential of Amgen's own GLP-1 pipeline candidates.Bearish1-5y0.60
    2026-09-17Eli Lilly Expands US Oral GLP-1 Foundayo Prescriptions to 47.5K Against WegovyIncreased competitive intensity in the GLP-1 market, potentially raising the bar for efficacy and market penetration for pipeline candidates.watch3-12m0.40
    2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel PathwaysValidation of novel therapeutic approaches, potential for future pipeline expansion or partnerships in cardiovascular diseases, especially given their existing cardiovascular portfolio.Bullish1-3m0.65
    2026-09-13Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoYIncreased competitive intensity in the immunology market, potentially affecting market share and growth prospects for Amgen's immunology assets.Bearish3-12m0.50
    2026-09-13Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 on Taltz and New LaunchesCompetitive landscape in the immunology market. LLY's strong immunology growth, particularly with Taltz (psoriasis/psoriatic arthritis), could pose a competitive challenge to AMGN's immunology assets like Otezla and Enbrel.mixed3-12m0.50
    2026-09-13Eli Lilly Expands Non-Incretin Growth as Immunology Revenue Hits $2.6B in H1Indirect competitive pressure in the immunology market. LLY's expanding portfolio and strong performance could impact the broader competitive landscape.mixed3-12m0.30
    2026-09-13Eli Lilly Immunology Division Reaches $2.6 Billion Revenue in H1 2026Similar to J&J, Amgen faces direct competition in the immunology space. LLY's strong performance could signal a more challenging competitive landscape.mixed3-12m0.40
    2026-09-12Eli Lilly Immunology Division Reaches $2.6B in H1 2026 on Taltz and New LabelsIncreased competitive pressure in the immunology market, potentially affecting market share for drugs like Otezla and Enbrel.mixed3-12m0.30
    2026-09-12Eli Lilly H1 Immunology Revenue Hits $2.6B via Taltz and M&A PipelineEli Lilly's expanding immunology portfolio and M&A activity could intensify competition for Amgen's immunology assets, potentially affecting future market share and growth prospects.mixed3-12m0.40
    2026-09-12Eli Lilly Immunology Division Generates $2.6B in H1 2026 RevenueCompetitive landscape in immunology; market share dynamics.mixed3-12m0.50
    2026-09-12Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&AIncreased competitive dynamics in the immunology market, potentially impacting Amgen's existing immunology portfolio (e.g., Otezla, Enbrel) or future pipeline assets.mixed3-12m0.30
    2026-09-12Eli Lilly Immunology Revenue Reaches $2.6B in H1, Growing 9% Year-Over-YearIncreased competitive intensity in the immunology market from Eli Lilly's expanding portfolio, potentially affecting Amgen's immunology drug sales (e.g., Otezla, Enbrel) or requiring increased R&D/marketing spend.mixed3-12m0.30
    2026-09-12Eli Lilly immunology sales reach $2.6B in H1 2026, rising 9% YoYPotential for increased competitive pressure in the immunology market. Amgen has a presence in immunology (e.g., Otezla, biosimilars to Humira), and Lilly's strong performance could signal a more crowded and competitive environment, potentially impacting Amgen's growth prospects in this therapeutic mixed3-12m0.20

    Continue this research

    Build your Amgen Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the AMGN entity page →

    Research Amgen Inc. · $399/mo